Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review

Acute Myeloid Leukaemia in Children

Brenda E. S. Gibson  1 , Martin G. Sauer  2 , Subramaniam Ramanathan  3 , Persis J. Amrolia  4
Anna Sureda  1 , Selim Corbacioglu  2 , Raffaella Greco  3 , Nicolaus Kröger  4 , Enric Carreras  5
, editors.
In: The EBMT Handbook: Hematopoietic Cell Transplantation and Cellular Therapies [Internet]. 8th edition. Cham (CH): Springer; 2024. Chapter 71.
.
Affiliations
Free Books & Documents
Review

Acute Myeloid Leukaemia in Children

Brenda E. S. Gibson et al.
Free Books & Documents

Excerpt

The outcome for children with acute myeloid leukaemia (AML) continues to improve although not at the pace of acute lymphoblastic leukaemia (ALL). The current 3-year EFS and OS are 65–70% and 75–80%, respectively. The improved survival is attributed to better supportive care, refinement in risk stratification (particularly directing patients to allogeneic HCT in CR1), and improved salvage in relapsed/refractory AML (R/R AML). The enhanced understanding of the genomic landscape of paediatric AML has lead to the strategic use of novel treatments. The future of AML treatment lies in optimising the therapeutic potential of new treatments, including CAR T-cells, in combination with conventional chemotherapy and allogeneic HCT.

PubMed Disclaimer

References

    1. Abrahamsson J, Forestier E, Heldrup J, et al. Response-guided induction therapy in pediatric acute myeloid leukemia with excellent remission rate. J Clin Oncol. 2011;29:310–5. - PubMed
    1. Andersson BS, Valdez BC, de Lima M, et al. Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS. Biol Blood Marrow Transplant. 2011;17(6):893–900. https://doi.org/10.1016/j.bbmt.2010.09.022. Epub 2010 Oct 11 - DOI - PMC - PubMed
    1. Ayala E, Figueroa J, Perkins J, et al. Myeloablative intravenous pharmacokinetically targeted busulfan plus fludarabine as conditioning for allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk. 2015;15(6):335–40. https://doi.org/10.1016/j.clml.2014.12.016. Epub 2015 Jan 7 - DOI - PubMed
    1. Bertaina A, Zecca M, Buldini B, et al. Unrelated donor vs HLA-haploidentical α/β T-cell- and B-cell-depleted HSCT in children with acute leukemia. Blood. 2018;132(24):2594–607. https://doi.org/10.1182/blood-2018-07-861575. Epub 2018 Oct 22 - DOI - PubMed
    1. Booth N, Mirea L, Huschart E, Miller H, et al. Efficacy of Azacitidine and Prophylactic Donor Lymphocyte Infusion after HSCT in Pediatric Patients with Acute Myelogenous Leukemia: A Retrospective Pre-Post. StudyTransplant Cell Ther. 2023;29(5):330.e1–7. https://doi.org/10.1016/j.jtct.2023.02.009. Epub 2023 Feb 19 - DOI - PubMed

LinkOut - more resources